Radial or femoral access in primary percutaneous coronary intervention (PCI): Does the choice matters?


Journal

Indian heart journal
ISSN: 2213-3763
Titre abrégé: Indian Heart J
Pays: India
ID NLM: 0374675

Informations de publication

Date de publication:
Historique:
received: 12 12 2019
revised: 07 05 2020
accepted: 10 05 2020
entrez: 10 8 2020
pubmed: 10 8 2020
medline: 18 3 2021
Statut: ppublish

Résumé

This study was conducted with the aim of providing a quantitative appraisal of clinical outcomes of trans-radial access for primary percutaneous coronary interventions (PCI) in patients with ST-segment evaluation myocardial infarction (STEMI). In this study, we compared two propensity-matched cohorts of patients who underwent primary PCI via trans-radial (TRA) and trans-femoral access (TFA) in a 1:1 ratio. The profile of two cohorts was matched for gender, age, and body mass index, diabetes, hypertension, family history, and smoking. The outcomes of primary PCI were compared for the two cohorts which included all-cause in-hospital mortality, heart failure, re-infarction, cardiogenic shock, bleeding, transfusion, cerebrovascular accident, and dialysis. This analysis was performed on a total of 2316 patients with 1158 patients each in the TRA and TFA group. We observed significantly lower rates of mortality, 0.8% (9) vs. 3.5% (41); p < 0.001 and bleeding, 0.5% (6) vs.1.6% (19); p = 0.009 with shorter hospital stay, 1.61 ± 1.39 vs. 1.98 ± 1.5 days, in trans-radial vs. trans-femoral. However, both fluoroscopic time and contrast volume were significantly higher in the TRA as compared to TFA group 15.57 ± 8.16 vs. 12.79 ± 7.82 min; p < 0.001 and 143.22 ± 45.33 vs. 133.78 ± 45.97; p < 0.001 respectively. Compared with TFA access, TRA for primary PCI is safe for patients with STEMI, it was found to be associated with a significant reduction in in-hospital mortality and bleeding complications.

Sections du résumé

BACKGROUND BACKGROUND
This study was conducted with the aim of providing a quantitative appraisal of clinical outcomes of trans-radial access for primary percutaneous coronary interventions (PCI) in patients with ST-segment evaluation myocardial infarction (STEMI).
METHODS METHODS
In this study, we compared two propensity-matched cohorts of patients who underwent primary PCI via trans-radial (TRA) and trans-femoral access (TFA) in a 1:1 ratio. The profile of two cohorts was matched for gender, age, and body mass index, diabetes, hypertension, family history, and smoking. The outcomes of primary PCI were compared for the two cohorts which included all-cause in-hospital mortality, heart failure, re-infarction, cardiogenic shock, bleeding, transfusion, cerebrovascular accident, and dialysis.
RESULTS RESULTS
This analysis was performed on a total of 2316 patients with 1158 patients each in the TRA and TFA group. We observed significantly lower rates of mortality, 0.8% (9) vs. 3.5% (41); p < 0.001 and bleeding, 0.5% (6) vs.1.6% (19); p = 0.009 with shorter hospital stay, 1.61 ± 1.39 vs. 1.98 ± 1.5 days, in trans-radial vs. trans-femoral. However, both fluoroscopic time and contrast volume were significantly higher in the TRA as compared to TFA group 15.57 ± 8.16 vs. 12.79 ± 7.82 min; p < 0.001 and 143.22 ± 45.33 vs. 133.78 ± 45.97; p < 0.001 respectively.
CONCLUSIONS CONCLUSIONS
Compared with TFA access, TRA for primary PCI is safe for patients with STEMI, it was found to be associated with a significant reduction in in-hospital mortality and bleeding complications.

Identifiants

pubmed: 32768015
pii: S0019-4832(20)30094-8
doi: 10.1016/j.ihj.2020.05.004
pmc: PMC7411101
pii:
doi:

Types de publication

Comparative Study Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

166-171

Informations de copyright

Copyright © 2020 Cardiological Society of India. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest All authors have none to declare.

Références

J Invasive Cardiol. 1996;8 Suppl D:40D-44D
pubmed: 10785786
Heart. 2009 Oct;95(19):1612-8
pubmed: 19596690
Am Heart J. 2009 Jan;157(1):132-40
pubmed: 19081409
Am Heart J. 2018 Apr;198:46-54
pubmed: 29653648
Circulation. 2013 Jun 11;127(23):2295-306
pubmed: 23753843
Am Heart J. 2013 Mar;165(3):338-43
pubmed: 23453102
Circ Cardiovasc Qual Outcomes. 2014 Jul;7(4):550-9
pubmed: 24899678
Cathet Cardiovasc Diagn. 1993 Oct;30(2):173-8
pubmed: 8221875
J Am Coll Cardiol. 2004 Jul 21;44(2):349-56
pubmed: 15261930
Am Heart J. 2014 Jun;167(6):900-8.e1
pubmed: 24890541
J Am Coll Cardiol. 2012 Dec 18;60(24):2481-9
pubmed: 22858390
Am Heart J. 2015 Aug;170(2):353-61
pubmed: 26299234
Catheter Cardiovasc Interv. 2007 Nov 1;70(5):670-5
pubmed: 17563094
Am J Cardiol. 2005 Nov 1;96(9):1200-6
pubmed: 16253582
Lancet. 2011 Apr 23;377(9775):1409-20
pubmed: 21470671
Am Heart J. 2012 Apr;163(4):632-48
pubmed: 22520530
Am Heart J. 2005 Sep;150(3):543-9
pubmed: 16169338
JACC Cardiovasc Interv. 2013 Aug;6(8):814-23
pubmed: 23968700
Circulation. 2006 Aug 22;114(8):774-82
pubmed: 16908769
Cathet Cardiovasc Diagn. 1989 Jan;16(1):3-7
pubmed: 2912567
Lancet. 2015 Jun 20;385(9986):2465-76
pubmed: 25791214
Am Heart J. 1999 Sep;138(3 Pt 1):430-6
pubmed: 10467191

Auteurs

Mahesh Kumar Batra (MK)

National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan. Electronic address: Mahesh_bcmc@yahoo.com.

Lajpat Rai (L)

National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan.

Naveed Ullah Khan (NU)

National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan.

Muhammad Naeem Mengal (MN)

National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan.

Sanam Khowaja (S)

National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan.

Syed Nadeem Hassan Rizvi (SN)

National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan.

Tahir Saghir (T)

National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan.

Nadeem Qamar (N)

National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan.

Jawaid Akbar Sial (JA)

National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan.

Musa Karim (M)

National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH